PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(02): 151-156
DOI: 10.1055/s-0041-1733304
Original Article

Study of Bone Marrow Lymphocyte Subset in Acute Myeloid Leukemia

Prasad Dange
1   Department of Pathology, Grant Government Medical College, Mumbai, Maharashtra, India
,
Seema Tyagi
2   Department of Hematology, All India Institute of Medical Science, New Delhi, India
,
Richa Juneja
3   Department of Pathology, All India Institute of Medical Sciences, Nagpur, Maharashtra, India
,
Tulika Seth
2   Department of Hematology, All India Institute of Medical Science, New Delhi, India
,
Renu Saxena
4   Department of Hematopathology, Medanta Hospital, Gurugram, Haryana, India
› Institutsangaben
Funding None.
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Introduction Acute myeloid leukemia (AML) is a heterogenous disorder consisting of clonal expansion of myeloblasts. Tumor immunity plays an important part in the pathobiology of AML. Understanding the components of tumor immunity is important for understanding tumor pathogenesis and the principles of immunotherapy.

Methods We studied 41 patients with AML, for total lymphocyte, CD4 positive helper T cells, CD8 positive cytotoxic T cells, and CD16/56 positive natural killer (NK) cells proportion. Quantification was done on bone marrow aspirate sample by flowcytometry. Whenever available, post induction bone marrow was also analyzed for the lymphocyte subset.

Results No significant difference was noted in the percentage of blasts among the three risk categories: favorable, intermediate, and adverse. However, there was significant difference in the total lymphocyte among the risk stratification groups, being highest in the favorable group and lowest in the adverse group. CD8 positive cytotoxic T cells were significantly less in Acute Promyelocytic Leukemia (APML) cases (p = 0.001). Total lymphocytes were, however, more numerous in APML (p = 0.005). NK cell proportion was not significantly different between APML and non-APML patients.

On completion of induction chemotherapy, bone marrow samples for 12 patients could be processed for lymphocyte subset. On comparing the baseline against the post induction bone marrow, it was observed that there was significant increment in the proportion of CD4 positive T lymphocytes (p = 0.046).

Conclusion There is a difference in lymphocyte subset amongst patients with AML. Larger studies including functional aspects are needed to better define the role of lymphocytes in disease pathogenesis.

Keywords

acute myeloid leukemia - immunity - flowcytometry - lymphocyte subset

Presentation

Data earlier presented at Hematocon 2019, New Delhi. The study was approved by the Institutional Review Board.


Author Contribution

P.D. contributed toward study design, data collection, and manuscript preparation. S.T. did the study design, data analysis, and manuscript review. R.J. prepared the manuscript. T.S. did the manuscript review and supervision. R.S. did the data analysis, manuscript review, and supervision.




Publikationsverlauf

Artikel online veröffentlicht:
29. Juli 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India